Genetic Testing

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraisePrenetics invests $1.5M in Bitcoin, Solana...

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx...

GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment

UNC Health to Become the First Health System to Collaborate with GeneDx Through Aura, Epic’s Specialty Diagnostic SuiteGAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx...

UMC Utrecht adopts Volta Labs Callisto Sample Prep System to process thousands of samples for Whole Genome Sequencing-based prenatal and postnatal testing

BOSTON, Feb. 5, 2025 /PRNewswire/ -- Volta Labs, a leading genomics applications company, and UMC Utrecht, one of the largest public...

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc....

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies...

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed...

Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --...

error: Content is protected !!